课题基金 / 基金详情

项目摘要

项目成果

CURT I CIVIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lymphohematopoietic stem/progenitor cell biology is the long-term interest of Dr. Civin's laboratory. In addition, as clinical hematologist- oncologists, we desire to make direct application of our work to clinical treatment, especially stem/progenitor cell transplantation. Further understanding of the biology of human stem/progenitor cells is essential for many basic questions with clinical relevance, since these are the cells of origin of severe aplastic anemias (SAA), myelodysplastic syndromes (MDS) and leukemias, and because purified stem/progenitor cells are powerful therapeutic tools, especially (though not exclusively) for hematologic disorders. Development for feasible laboratory assays for human lymphohematopoietic stem cells (HSC) is important for basic understanding of hematopoiesis and for clinical BMT. New assays for HSC must be validated by clinical transplantation of candidate HSC, since human transplantation is currently the only way to definitively prove the presence of human HSC in the graft. Specific Aim 1 of Project 2 will extensively characterize "SCID repopulating cells" (SRC), the normal human hematopoietic cells which engraft in irradiated immunodeficient mice, with respect to immunophenotype. SRC will be compared with normal human and murine HSC. Specific Aim 2 will determine the effects of short-term ex vivo culture, an important approach in hematopoietic transplantation, on SRC. Specific Aim 3 will assess the use of SRC assays in cases of SAA, MDS, leukemias, and pediatric solid tumors. This may allow better definition of cancer stem cells, the cells which cause relapse. The laboratory investigation of normal and malignant stem/progenitor cell biology in Project 2 is central to the entire Program Project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia
  • 批准号:
    10290284
  • 项目类别:
  • 资助金额:
    $21.67万
  • 财政年份:
    2021
  • 负责人:
    CURT I CIVIN
  • 依托单位:
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia
  • 批准号:
    10457407
  • 项目类别:
  • 资助金额:
    $17.7万
  • 财政年份:
    2021
  • 负责人:
    CURT I CIVIN
  • 依托单位:
Microfluidic CAR-T Cell Processing Device
  • 批准号:
    9929262
  • 项目类别:
  • 资助金额:
    $92.44万
  • 财政年份:
    2018
  • 负责人:
    CURT I CIVIN
  • 依托单位:
High Efficiency Microfluidic Purification of Stem Cells to Improve Transplants
  • 批准号:
    8313288
  • 项目类别:
  • 资助金额:
    $24.13万
  • 财政年份:
    2012
  • 负责人:
    CURT I CIVIN
  • 依托单位:
海外基金